

## AMENDMENT

### Listing of the Claims

The following listing of claims replaces all previous listings or version thereof:

1. (Currently amended) A method of treating pathologic cardiac hypertrophy or heart failure in a human patient comprising:
  - (a) identifying a human patient having cardiac hypertrophy or heart failure; ~~and~~
  - (b) administering to said patient an inhibitor of Protein Kinase D (PKD); and
  - (c) administering to said patient a second cardiac hypertrophic therapy.
2. (Original) The method of claim 1, wherein said inhibitor of PKD is selected from the group consisting of resveratrol, indolocarbazoles, Godecke 6976 (Go6976), staurosporine, K252a, Substance P (SP) analogues including [d-Arg(1),d-Trp(5,7,9), Leu(11)]SP, PKC inhibitor 109203X (GF-1), PKC inhibitor Ro 31-8220, GO 7874, Genistein, the specific Src inhibitors PP-1 and PP-2, chelerythrine, rottlerin, a PKD RNAi molecule, a PKD antisense molecule, a PKD ribozyme molecule or a PKD-binding single-chain antibody, or expression construct that encodes a PKD-binding single-chain antibody.
3. (Original) The method of claim 1, wherein administering the inhibitor of PKD is performed intravenously or by direct injection into cardiac tissue.
4. (Original) The method of claim 1, wherein administering comprises oral, transdermal, sustained release, controlled release, delayed release, suppository, or sublingual administration.
5. (Canceled)

6. (Currently amended) The method of claim [[5]]1, wherein said second therapy is selected from the group consisting of a beta blocker, an ionotrope, a diuretic, ACE-I, AII antagonist, BNP, a  $\text{Ca}^{++}$ -blocker, or an HDAC inhibitor.
7. (Currently amended) The method of claim [[5]]1, wherein said second therapy is administered at the same time as said inhibitor of PKD.
8. (Currently amended) The method of claim [[5]]1, wherein said second therapy is administered either before or after said inhibitor of PKD.
9. (Original) The method of claim 1, wherein treating comprises improving one or more symptoms of pathologic cardiac hypertrophy.
10. (Original) The method of claim 1, wherein treating comprises improving one or more symptoms of heart failure.
11. (Original) The method of claim 9, wherein said one or more improved symptoms comprises increased exercise capacity, increased cardiac ejection volume, decreased left ventricular end diastolic pressure, decreased pulmonary capillary wedge pressure, increased cardiac output, or cardiac index, lowered pulmonary artery pressures, decreased left ventricular end systolic and diastolic dimensions, decreased left and right ventricular wall stress, decreased wall tension, increased quality of life, and decreased disease related morbidity or mortality.
- 12-99. (Canceled)
100. (Previously presented) The method of claim 1, wherein treating pathologic cardiac hypertrophy or heart failure further comprises increasing exercise tolerance, reducing hospitalizations, improving quality of life, decreasing morbidity, or decreasing mortality in a subject with heart failure or cardiac hypertrophy.